AIDXHealthcare · Medical Devices

AIDX Stock Forecast: 20/20 Biolabs, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.16
−12.72% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$2.2M
Ticker Nerd rank
20/ 100
Median analyst target
$5.00
Analysts covering
—
Revenue$731K
Operating income−$1.2M
Net income−$1.5M
Free cash flow−$613K
Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−21.5%
1M
−41.8%
From high
−99.3%
From low
0.0%
$0
$24
Range since 19 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores 20/20 Biolabs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
20/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
86
Issuance
49
Revisions
38
Value
20
Growth
10
Momentum
10
Quality
10
Volatility
3

Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AIDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 19 Feb 2026Adjusted close, US dollars
$0$5$10$15$20$25Apr 26Jul 26Oct 26AIDXHigh $5.00Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026Maxim GroupInitiatesBuy$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AIDX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AIDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

AIDX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Apr 26Jul 26Oct 26AIDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AIDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 63% of US stocks

Price / book
3.4×

Cheaper than 27% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−9.0%

Higher than 17% of US stocks

Earnings growth (YoY)
—
Gross margin
41.7%

Higher than 52% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−559.2%

Higher than 2% of US stocks

Return on assets
−75.5%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 20/20 Biolabs, Inc. has a market value of $2.2M and an enterprise value of $975K.

  • Revenue in the twelve months to 30 June 2026: $2.0M.

  • Net income over the same four quarters: −$5.8M, a −285.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.8M.

  • Shares outstanding: 12.3M.

  • 20/20 Biolabs, Inc. employs 4 people — $510K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AIDX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AIDX20/20 Biolabs, Inc.$2.2M20
IVFINVO Fertility, Inc.$2.1M29
BJDXBluejay Diagnostics, Inc.$1.9M17
NUWENuwellis, Inc.$1.8M18
PFSAProfusa, Inc.$1.8M19
TNONTENON Medical, Inc.$2.4M45
VVOSVivos Therapeutics, Inc.$1.8M43

Take a look at AIDX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own 20/20 Biolabs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AIDX

How does Ticker Nerd's model rank AIDX?

As at 21 Nov 2026, 20/20 Biolabs, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).

What is the AIDX stock forecast for 2030?

No analyst covering 20/20 Biolabs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

What does 20/20 Biolabs, Inc. do?

20/20 Biolabs, Inc. is a commercial-stage diagnostics company focused on AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company’s core offerings include the OneTest family, which covers multi-cancer early detection testing and longevity-related biomarker analysis.

Company

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. is a commercial-stage diagnostics company focused on AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company’s core offerings include the OneTest family, which covers multi-cancer early detection testing and longevity-related biomarker analysis. It also operates CLIAx, a clinical laboratory innovation platform that supports diagnostic development and testing workflows for emerging health technology companies. 20/20 Biolabs serves the healthcare diagnostics market with products and services designed to improve clinical utility through machine learning and real-world data. Based in Gaithersburg, Maryland, the company plays a role in expanding access to advanced laboratory testing and supporting broader adoption of precision diagnostics.

CEO Mr. Jonathan Cohen · 4 employees · United States · https://2020biolabs.com